United States Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and Forecasts, 2026-2035

Last Updated: September 01, 2026 | Author: Dhanashri Chandgude | Format:

United States Tulathromycin Market Size

The United States tulathromycin market size was valued at USD 396 million in 2025 and is projected to grow from USD 430.85 million in 2026 to reach USD 845.97 million by 2034, growing at a CAGR of 8.8% during the forecast period 2026–2034.

In the U.S. cattle industry, BRD remains the leading cause of morbidity and mortality in feedlots, resulting in poor performance, carcass quality, and animal health losses. Tulathromycin is an antibiotic that works by inhibiting the growth of bacteria. In veterinary medicine, it is typically administered to treat respiratory conditions in cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.

Download a Free Sample To learn more about this report.

Animals Insights

Cattle dominates the market and is expected to register a CAGR of 4.6% over the forecast period. For the treatment and prevention of bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cats, tulathromycin is used. In the United States dairy industry, respiratory disease plays a significant role in weaned calf mortality, and morbidity due to BRD negatively impacts survivability and dairy performance later in life.

United States Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

United States Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Country Insights

The United States tulathromycin market represents a sizeable portion of the global veterinary antibiotics business. The effectiveness of the broad-spectrum antibiotic tulathromycin in treating respiratory infections in animals has made it famous. It is mostly employed in veterinary medicine. Several factors, including the rising pet ownership rate, the expansion of the livestock industry, and the rising need for animal protein, fuel the market.

With a sizable population of cattle, swine, and poultry, the United States has a thriving and highly developed livestock industry. Livestock farmers are challenged with keeping their animals healthy and productive as consumer demand for meat and dairy products rises. Tulathromycin is useful for treating livestock bacterial infections and respiratory illnesses, ensuring their health and maximizing productivity.

Additionally, the rising pet ownership rate in the United States increases the demand for tulathromycin. Companion animals, like dogs and cats, are valued parts of families, and pet owners place a high priority on their health and well-being. Tulathromycin treats various infections and ailments in pets, allowing vets to give these creatures better care and a higher quality of life.

List of Key and Emerging Players in United States Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

March 2026

Huvepharma expanded its injectable veterinary antibiotic portfolio in the United States by increasing production capacity and strengthening distribution of tulathromycin formulations for livestock health management.

October 2025

Norbrook Laboratories strengthened its U.S. animal health business by expanding its generic tulathromycin injection portfolio for food-producing animals, improving product availability for veterinary practitioners.

August 2025

Merck Animal Health expanded its cattle and swine respiratory disease management portfolio through enhanced veterinary support programs and broader availability of tulathromycin injectable therapies.

May 2025

Zoetis expanded its U.S. livestock health portfolio by strengthening production and distribution of tulathromycin-based injectable antibiotics for the treatment of bovine and swine respiratory diseases.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

According to Straits Research, the United States tulathromycin market size is projected to grow at USD 430.85 million in 2026.

High prevalence of BRD and SRD is the key driver for the growth of this market.

The key players in this market are The Zoetis,Zhejiang Genebest Pharmaceutical,Wisdom Pharmaceutical,Amicogen Biopharm,Hubei Honch Pharmaceutical Livzon New North River Pharmaceutical,AVF Chemical Industrial,Jiangsu Lingyun Pharmaceutical.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.